The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population

Heart and Vessels

Volumn 25, Issue 2, 2010, Pages 155-162

  Ozer, Nihat ^a,c   Cam, Nese ^a   Tangurek, Burak ^a   Ozer, Songul ^a   Uyarel, Huseyin ^a   Oz, Dilaver ^a   Guney, Mehmet Rasit ^a   Ciloglu, Figen ^b  

^a DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GenLab Genetic Medical Laboratories Istanbul   (Turkey)

^c Selami Ali Mah Bakkaladem Sok   (Turkey)

Author keywords

CYP2C9; Genetic; Thromboembolism; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE 1; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; BODY SURFACE; CLINICAL EVALUATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG USE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC DIFFERENCE; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HOMOZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROTHROMBIN TIME; TREATMENT PLANNING; TURKEY (REPUBLIC); WILD TYPE;

ADULT; AGE FACTORS; AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; BODY SURFACE AREA; CHI-SQUARE DISTRIBUTION; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENOTYPE; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; TURKEY; WARFARIN; YOUNG ADULT;

EID: 77950921691     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-009-1177-7     Document Type: Article

References (56)

1. J. Hirsch J.E. Dalen D.R. Anderson L. Poller H. Bussey J. Ansell 1998 Oral anticoagulants: mechanisms of action, clinical effectiveness and optimal therapeutic range Chest 114 445 469 10.1378/chest.114.5-Supplement.445S (Pubitemid 28535775)
2. A.M. Van den Besselaar 1985 Standardization of the prothrombin time in oral anticoagulant control Haemostasis 15 271 277 4043828 (Pubitemid 16248327)
3. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis 1994 Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction Lancet 343 499 503 (Pubitemid 124000792)
4. S.C. Cannegieter F.R. Rosendaal A.R. Wintzen F.J. Van Der Meer J.P. Vandenbroucke E. Briet 1995 Optimal oral anticoagulant therapy in patients with mechanical heart valves N Engl J Med 333 11 17 10.1056/NEJM199507063330103 1:STN:280:DyaK2M3psFOmtw%3D%3D 7776988
5. S.D. Fihn M. McDonell D. Martin J. Henikoff D. Vermes D. Kent R.H. White 1993 Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group Ann Intern Med 118 511 520 1:STN:280:DyaK3s7ot1yqsg%3D%3D 8280198
6. Stroke Prevention in Atrial Fibrillation Investigators 1996 Bleeding during antithrombotic therapy in patients with atrial fibrillation Arch Intern Med 156 409 416 10.1001/archinte.156.4.409 (Pubitemid 26067316)
7. Stroke Prevention in Atrial Fibrillation Investigators 1996 Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial Lancet 348 633 638 10.1016/S0140-6736(96)03487-3 (Pubitemid 26293807)
8. R. Loebstein H. Yonath D. Peleg S. Almog M. Rotenberg A. Lubetsky J. Roitelman D. Harats H. Haklin D. Ezra 2001 Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 70 159 164 10.1067/mcp.2001.117444 1:CAS:528:DC%2BD3MXmslygs74%3D 11503010 (Pubitemid 32777768)
9. M.A. Hillman R.A. Wilke M.D. Caldwell R.L. Berg I. Glurich J.K. Burmester 2004 Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype Pharmacogenetics 14 539 547 10.1097/01.fpc.0000114760.08559.dc 1:CAS:528:DC%2BD2cXmtVGgtbg%3D 15284536 (Pubitemid 39100005)
10. F. Kamali T.I. Khan B.P. King R. Frearson P. Kesteven P. Wood A.K. Daly H. Wynne 2004 Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin Clin Pharmacol Ther 75 204 212 10.1016/j.clpt.2003.10.001 1:CAS:528:DC%2BD2cXhslenurk%3D 15001972 (Pubitemid 38314870)
11. V. Franco C.A. Polanczyk N. Clausell L.E. Rohde 2004 Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols Am J Med 116 651 656 10.1016/j.amjmed. 2003.12.036 1:CAS:528:DC%2BD2cXjs1Wksb8%3D 15121490 (Pubitemid 38581109)
12. H.M. Yu T.Y.K. Chan J.A.J.H. Critchley K.S. Woo 1996 Factors determining the maintenance dose of warfarin in Chinese patients Q J Med 89 127 135 1:STN:280:DyaK28zgs1GksA%3D%3D
13. A. Blann J. Hewitt F. Siddiqui D. Bareford 1999 Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0 Br J Haematol 107 207 209 10.1046/j.1365-2141.1999.01672.x 1:CAS:528:DyaK1MXnsVehsLs%3D 10520043 (Pubitemid 29500828)
14. R.K. Absher M.E. Moore M.H. Parker 2002 Patient-specific factors predictive of warfarin dosage requirements Ann Pharmacother 36 1512 1517 10.1345/aph.1C025 12243598
15. G.G. Gan A. Teh K.Y. Goh H.T. Chong K.W. Pang 2003 Racial background is a determinant factor in the maintenance dosage of warfarin Int J Hematol 78 84 86 10.1007/BF02983247 1:CAS:528:DC%2BD3sXmsl2rur8%3D 12894858
16. H. Takahashi G.R. Wilkinson Y. Caraco M. Muszkat R.B. Kim T. Kashima S. Kimura H. Echizen 2003 Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients Clin Pharmacol Ther 73 253 263 10.1067/mcp.2003.26a 1:CAS:528:DC%2BD3sXitFagt7g%3D 12621390 (Pubitemid 36269676)
17. F. Zhao C. Loke S.C. Rankin J.Y. Guo H.S. Lee T.S. Wu T. Tan T.C. Liu W.L. Lu Y.T. Lim Q. Zhang B.C. Goh S.C. Lee 2004 Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose Clin Pharmacol Ther 76 210 219 10.1016/j.clpt.2004.05.005 1:CAS:528: DC%2BD2cXnslKks7s%3D 15371982 (Pubitemid 39221795)
18. J.O. Miners D.J. Birkett 1998 Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Br J Clin Pharmacol 45 525 538 10.1046/j.1365-2125.1998.00721.x 1:CAS:528:DyaK1cXktFaitro%3D 9663807 (Pubitemid 28270907)
19. F. Yildiz B. Kurtaran M. Çayli A. Candevir Z. Sümbül 2008 A significant interaction between moxifloxacin and warfarin in a patient with a mitral bioprosthetic valve Heart Vessels 23 286 288 10.1007/s00380-008- 1050-0 18649061
20. R.A. O'Reilly 1974 Studies on the optical enantiomorphs of warfarin in man Clin Pharmacol Ther 16 348 354 4605176
21. G.P. Aithal C.P. Day P.J.L. Ketseven A.K. Daly 1999 Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 717 719 10.1016/S0140-6736(98)04474-2 1:STN:280:DyaK1M7ntFGhsQ%3D%3D 10073515 (Pubitemid 29103806)
22. M.K. Higashi D.L. Veenstra L.M. Kondo A.K. Wittkowsky S.L. Srinouanprachanh F.M. Farin A.E. Rettie 2002 Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 1690 1698 10.1001/jama.287.13.1690 1:CAS:528:DC%2BD38XisFaru7c%3D 11926893
23. M.G. Scordo V. Pengo E. Spina M.L. Dahl M. Gusella R. Padrini 2002 Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearence Clin Pharmacol Ther 72 702 710 10.1067/mcp.2002. 129321 1:CAS:528:DC%2BD3sXlt1Sjug%3D%3D 12496751 (Pubitemid 36021009)
24. D.L. Veenstra D.K. Blough M.K. Higashi F.M. Farin S. Srinouanprachan M.J. Rieder A.E. Rettie 2005 CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes Clin Pharmacol Ther 77 353 364 10.1016/j.clpt.2005.01.019 1:CAS:528:DC%2BD2MXktFCrt7s%3D 15900281 (Pubitemid 40719264)
25. D. Cain S.M. Hutson R. Wallin 1997 Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane J Biol Chem 272 29068 29075 10.1074/jbc.272.46.29068 1:CAS:528:DyaK2sXnsVKqsrs%3D 9360981 (Pubitemid 27498194)
26. S. Rost A. Fregin V. Ivaskevicius E. Conzelmann K. Hörtnagel H.J. Pelz K. Lappegard E. Seifried I. Scharrer E.G. Tuddenham C.R. Müller T.M. Strom J. Oldenburg 2004 Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor defi- ciency type 2 Nature 427 537 541 10.1038/nature02214 1:CAS:528:DC%2BD2cXpsFWhtQ%3D%3D 14765194 (Pubitemid 38209110)
27. G. D'Andrea R.L. D'Ambrosio P. Di Perna M. Chetta R. Santacroce V. Brancaccio E. Grandone M. Margaglione 2005 A polymorphisms in the VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin Blood 105 645 649 10.1182/blood-2004-06-2111 15358623 (Pubitemid 40070748)
28. L. Bodin C. Verstuyft D.A. Tregouet A. Robert L. Dubert C. Funck-Brentano P. Jaillon P. Beaune P. Laurent-Puig L. Becquemont M.A. Loriot 2005 Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinant of acenocoumarol sensitivity Blood 106 135 140 10.1182/blood-2005- 01-0341 1:CAS:528:DC%2BD2MXlvVWjsLo%3D 15790782 (Pubitemid 40967184)
29. H. Schelleman Z. Chen C. Kealey A.S. Whitehead J. Christie M. Price C.M. Brensinger C.W. Newcomb C.F. Thorn F.F. Samaha S.E. Kimmel 2007 Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians Clin Pharmacol Ther 81 5 742 747 10.1038/sj.clpt.6100144 1:CAS:528:DC%2BD2sXlsFCqtrg%3D 17329985 (Pubitemid 46625114)
30. N.A. Limdi J.A. Goldstein J.A. Blaisdell T.M. Beasley C.A. Rivers R.T. Acton 2007 Influence of CYP2C9 genotype on warfarin dose among African-Americans and European-Americans Pers Med 4 157 169 10.2217/17410541.4.2.157 1:CAS:528:DC%2BD2sXmslKrur4%3D (Pubitemid 46845895)
31. A.S. Aynacioglu J. Brockmöller S. Bauer C. Sachse P. Guzelbey Z. Ongen M. Nacak I. Roots 1999 Frequency of cytochrome P450 CYP2C9 variants in Turkish population and functional relevance for phenytoin Br J Clin Pharmacol 48 409 415 10.1046/j.1365-2125.1999.00012.x 1:CAS:528:DyaK1MXmsFehsLg%3D 10510154 (Pubitemid 29417726)
32. N. Dericioglu M.O. Babaoglu S. Saygi A. Bozkurt U. Yasar 2004 Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype Ann Pharmacother 38 899 15039471
33. G. Oner Ozgon T.Y. Langaee H. Feng N. Buyru T. Ulutin A.C. Hatemi A. Siva S. Saib J.A. Johnson 2008 VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients Eur J Clin Pharmacol 64 9 889 894 10.1007/s00228-008-0507-5 1:CAS:528:DC%2BD1cXhtVKju7bK 18542936
34. T. Li L.A. Lange X. Li L. Susswein B. Bryant R. Malone E.M. Lange T.Y. Huang D.W. Stafford J.P. Evans 2006 Polymorphism in the VKORC1 gene is strongly associated with warfarin dosage requirements in patients receiving anticoagulation J Med Genet 43 740 744 10.1136/jmg.2005.040410 1:CAS:528:DC%2BD28XhtFGrtL7N 16611750 (Pubitemid 44483917)
35. C. Geisen M. Watzka K. Sittinger M. Steffens L. Daugela E. Seifried C.R. Muller T.F. Wienker J. Oldenburg 2005 VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation Thromb Haemost 94 773 779 16270629
36. B.S. Oz F. Asgun K. Oz E. Kuralay H. Tatar 2007 Warfarin-induced skin necrosis after open heart surgery due to protein S and C deficiency Heart Vessels 22 64 66 10.1007/s00380-006-0935-z 17285450 (Pubitemid 46477194)
37. H. Wynne L. Cope P. Kelly T. Whittingham C. Edwards F. Kamali 1995 The influence of age, liver size and enantiomer concentrations on warfarin requirements Br J Pharmacol 40 203 207 1:CAS:528:DyaK2MXosl2lsbw%3D
38. G.A. Rosito R.B. D'Agostino J. Massaro I. Lipinska M.A. Mittleman P. Sutherland P.W. Wilson D. Levy J.E. Muller G.H. Tofler 2004 Association between obesity and a prothrombotic state: the Framingham Offspring Study Thromb Haemost 91 683 689 1:CAS:528:DC%2BD2cXjsVGrs78%3D 15045128
39. E.A. Sconce T.I. Khan H.A. Wynne P. Avery L. Monkhouse B.P. King P. Wood P. Kesteven A.K. Daly F. Kamali 2005 The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 2329 2333 10.1182/blood-2005-03-1108 1:CAS:528:DC%2BD2MXhtVKqt7%2FL 15947090 (Pubitemid 41510803)
40. M.S. Wen M. Lee J.J. Chen H.P. Chuang L.S. Lu C.H. Chen T.H. Lee C.T. Kuo F.M. Sun Y.J. Chang P.L. Kuan Y.F. Chen M.J. Charng C.Y. Ray J.Y. Wu Y.T. Chen 2008 Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes Clin Pharmacol Ther 84 83 89 10.1038/sj.clpt.6100453 1:CAS:528:DC%2BD1cXnt1KqsL4%3D 18183038 (Pubitemid 351861488)
41. M.J. Rieder A.P. Reiner B.F. Gage D.A. Nickerson C.S. Eby H.L. McLeod D.K. Blough K.E. Thummel D.L. Veenstra A.E. Rettie 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med 352 2285 2293 10.1056/NEJMoa044503 1:CAS:528:DC%2BD2MXksl2ltrk%3D 15930419 (Pubitemid 40740552)
42. M. Wadelius L.Y. Chen K. Downes J. Ghori S. Hunt N. Eriksson O. Wallerman H. Melhus C. Wadelius D. Bentley P. Deloukas 2005 Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J 5 262 270 10.1038/sj.tpj.6500313 1:CAS:528:DC%2BD2MXmsVyjs78%3D 15883587 (Pubitemid 41131718)
43. H. Takahashi G.R. Wilkinson E.A. Nutescu T. Morita M.D. Ritchie M.G. Scordo V. Pengo M. Barban R. Padrini I. Leiri K. Otsubo T. Kashima S. Kimura S. Kijima H. Echizen 2006 Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans Pharmacogen Genom 16 101 110 10.1097/01.fpc.0000184955.08453.a8 1:CAS:528:DC%2BD28Xls1Gksg%3D%3D
44. S.C. Lee S.S. Ng J. Oldenburg P.Y. Chong S. Rost J.Y. Guo H.L. Yap S.C. Rankin H.B. Khor T.C. Yeo K.S. Ng R. Soong B.C. Goh 2006 Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population Clin Pharmacol Ther 79 197 205 10.1016/j.clpt.2005.11.006 1:CAS:528:DC%2BD28XitVKhurw%3D 16513444
45. M. Vecsler R. Loebstein S. Almog D. Kurnik B. Goldman H. Halkin E. Gak 2006 Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin Thromb Haemost 95 205 211 1:CAS:528:DC%2BD28XisVSrtLw%3D 16493479
46. D. Herman P. Peternel M. Stegnar K. Breskvar V. Dolzan 2006 The influence of sequence variations in factor VII, gammaglutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement Thromb Haemost 95 782 787 1:CAS:528:DC%2BD28Xlt1WgtLc%3D 16676068
47. C.L. Aquilante T.Y. Langaee L.M. Lopez H. Yarandi J. Tromberg D. Mohuczy K. Gaston C. Waddell M. Chirico J. Johnson 2006 Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements Clin Pharmacol Ther 79 291 302 10.1016/j.clpt.2005.11.011 1:CAS:528:DC%2BD28XjtFaiur4%3D 16580898
48. D.L. Veenstra J.H. You M.J. Rieder F.M. Farin H.W. Wilkerson D.K. Blough G. Cheng A.E. Rettie 2005 Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population Pharmacogen Genom 15 687 691 10.1097/01.fpc.0000174789.77614.68 1:CAS:528:DC%2BD2MXpslahtLc%3D
49. K. Obayashi K. Nakamura J. Kawana H. Ogata K. Hanada M. Kurabayashi A. Hasegawa K. Yamamoto R. Horiuchi 1974 VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients Clin Pharmacol Ther 80 169 178 10.1016/j.clpt.2006.04.010
50. H.Y. Yuan J.J. Chen M.T. Lee J.C. Wung Y.F. Chen M.J. Charng M.J. Lu C.R. Hung C.Y. Wei C.H. Chen J.Y. Wu Y.T. Chen 2005 A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity Hum Mol Genet 14 1745 1751 10.1093/hmg/ddi180 1:CAS:528:DC%2BD2MXmvV2htL0%3D 15888487 (Pubitemid 41430097)
51. N.A. Limdi D.K. Arnett J.A. Goldstein T.M. Beasley G. McGwin B.K. Adler R.T. Acton 2008 Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans Pharmacogenomics 9 5 511 526 10.2217/14622416.9.5.511 1:CAS:528: DC%2BD1cXlvFyis74%3D 18466099 (Pubitemid 351803913)
52. J.F. Carlquist B.D. Horne J.B. Muhlestein D.L. Lapp'e B.M. Whiting M.J. Kolek J.L. Clarke B.C. James J.L. Anderson 2006 Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study J Thromb Thrombolysis 22 3 191 197 10.1007/s11239-006-9030-7 1:CAS:528:DC%2BD28Xht1yis7vM 17111199 (Pubitemid 44857780)
53. H. Schelleman Z. Chen C. Kealey A.S. Whitehead J. Christie M. Price C.M. Brensinger C.W. Newcomb C.F. Thorn F.F. Samaha S.E. Kimmel 2007 Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians Clin Pharmacol Ther 81 5 742 747 10.1038/sj.clpt.6100144 1:CAS:528:DC%2BD2sXlsFCqtrg%3D 17329985 (Pubitemid 46625114)
54. J.L. Anderson B.D. Horne S.M. Stevens A.S. Grove S. Barton Z.P. Nicholas S.F. Kahn H.T. May K.M. Samuelson J.B. Muhlestein J.F. Carlquist 2007 Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 2563 2570 10.1161/CIRCULATIONAHA.107. 737312 1:CAS:528:DC%2BD2sXhtlagsb3F 17989110 (Pubitemid 350179221)
55. E. Shikata I. Ieiri S. Ishiguro H. Aono K. Inoue T. Koide S. Ohgi K. Otsubo 2004 Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity Blood 103 2630 2635 10.1182/blood-2003-09- 3043 1:CAS:528:DC%2BD2cXjtVaks7o%3D 14656880 (Pubitemid 38393017)
56. L.E. Visser P.H. Trienekens P.A. De Smet A.G. Vulto A. Hofman C.M. van Duijn B.H. Stricker 2005 Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants Pharmacogen Genom 15 69 74 10.1097/01213011- 200502000-00002 1:CAS:528:DC%2BD2MXivFGjt7c%3D